Predictors of accelerated decline in lung function in adult-onset asthma

European Respiratory Journal

Volumn 51, Issue 2, 2018, Pages

  Coumou, Hanneke ^a   Westerhof, Guus A ^a   De Nijs, Selma B ^a   Zwinderman, Aeilko H ^a   Bel, Elisabeth H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CARBON MONOXIDE; CORTICOSTEROID; FLUTICASONE; HEMOGLOBIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASTHMA; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESPIRATORY TRACT ALLERGY; RISK FACTOR; UNIVARIATE ANALYSIS; ADOLESCENT; DISEASE EXACERBATION; FOLLOW UP; INFLAMMATION; LUNG FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; ONSET AGE; PATHOPHYSIOLOGY; PROCEDURES; PULMONOLOGY; QUESTIONNAIRE; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ASTHMA; BIOMARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY MEDICINE; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85046271644     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01785-2017     Document Type: Article

References (41)

1. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–224.
2. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
4. Sood A, Qualls C, Schuyler M, et al. Adult-onset asthma becomes the dominant phenotype among women by age 40 years. The longitudinal CARDIA study. Ann Am Thorac Soc 2013; 10: 188–197.
5. Kankaanranta H, Tuomisto LE, Ilmarinen P. Age-specific incidence of new asthma diagnoses in Finland. J Allergy Clin Immunol Pract 2017; 5: 189–191.
6. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 101–108.
7. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372: 1049–1057.
8. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 629–634.
9. ten Brinke A, van Dissel JT, Sterk PJ, et al. Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001; 107: 449–454.
10. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194–1200.
11. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30: 452–456.
12. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58: 322–327.
13. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116: 477–486.
14. Hansen EF, Phanareth K, Laursen LC, et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267–1271.
15. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24: 122–128.
16. Global Initiative for Asthma. Global strategy for asthma management and prevention 2002. Available from: http://ginasthma.org Date last accessed: September 2016.
17. Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902–907.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
19. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–615.
20. Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur Respir J 2002; 20: Suppl. 37, 3s–8s.
21. Tommola M, Ilmarinen P, Tuomisto LE, et al. The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J 2016; 48: 1298–1306.
22. Rijcken B, Schouten JP, Xu X, et al. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995; 151: 1377–1382.
23. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70: 171–179.
24. O’Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179: 19–24.
25. Marcon A, Corsico A, Cazzoletti L, et al. Body mass index, weight gain, and other determinants of lung function decline in adult asthma. J Allergy Clin Immunol 2009; 123: 1069–1074.
26. Chen Y, Horne SL, Dosman JA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. Thorax 1993; 48: 375–380.
27. van Veen IH, Ten Brinke A, Sterk PJ, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008; 32: 344–349.
28. Matsunaga K, Hirano T, Oka A, et al. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int 2016; 65: 266–271.
29. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153: 454–457.
30. O’Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006; 129: 1478–1485.
31. Galli J, Montuschi P, Passali GC, et al. Exhaled nitric oxide measurement in patients affected by nasal polyposis. Otolaryngol Head Neck Surg 2012; 147: 351–356.
32. Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013; 132: 336–341.
33. Jatakanon A, Lim S, Kharitonov SA, et al. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53: 91–95.
34. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35: 1175–1179.
35. Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005; 116: 1249–1255.
36. Pistelli F, Bottai M, Carrozzi L, et al. Changes in obesity status and lung function decline in a general population sample. Respir Med 2008; 102: 674–680.
37. Al-Alwan A, Bates JH, Chapman DG, et al. The nonallergic asthma of obesity. A matter of distal lung compliance. Am J Respir Crit Care Med 2014; 189: 1494–1502.
38. Beuther DA, Weiss ST, Sutherland ER. Obesity and asthma. Am J Respir Crit Care Med 2006; 174: 112–119.
39. Ilmarinen P, Tuomisto LE, Niemela O, et al. Cluster analysis on longitudinal data of patients with adult-onset asthma. J Allergy Clin Immunol Pract 2017; 5: 967–978.
40. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev 2016; 9: CD011440.
41. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev 2016; 11: CD011439.